Child's Nervous System

, Volume 35, Issue 11, pp 2043–2046 | Cite as

Bevacizumab in the treatment of radiation injury for children with central nervous system tumors

  • Nathan A. Dahl
  • Arthur K. Liu
  • Nicholas K. Foreman
  • Melissa Widener
  • Laura Z. Fenton
  • Margaret E. MacyEmail author
Brief Communication



Radiation-induced injury is a well-described toxicity in children receiving radiation therapy for tumors of the central nervous system. Standard therapy has historically consisted primarily of high-dose corticosteroids, which carry significant side effects. Preclinical models suggest that radiation necrosis may be mediated in part through vascular endothelial growth factor (VEGF) overexpression, providing the rationale for use of VEGF inhibitors in the treatment of CNS radiation necrosis. We present the first prospective experience examining the safety, feasibility, neurologic outcomes, and imaging characteristics of bevacizumab therapy for CNS radiation necrosis in children.


Seven patients between 1 and 25 years of age with neurologic deterioration and MRI findings consistent with radiation injury or necrosis were enrolled on an IRB-approved pilot feasibility study. Patients received bevacizumab at a dose of 10 mg/kg intravenously every 2 weeks for up to 6 total doses.


Five patients (83%) were able to wean off corticosteroid therapy during the study period and 4 patients (57%) demonstrated improvement in serial neurologic exams. All patients demonstrated a decrease in T1-weighted post-gadolinium enhancement on MRI, while 5 (71%) showed a decrease in FLAIR signal. Four patients developed a progressive disease of their underlying tumor during bevacizumab therapy.


Our experience lends support to the safety and feasibility of bevacizumab administration for the treatment of radiation necrosis for appropriately selected patients within the pediatric population.


Bevacizumab Radiation injury Radiation necrosis Pediatric 



Support for this study was provided by Genentech, Inc. Genentech US Drug Safety, 1 DNA Way Mailstop 258A, South San Francisco, CA 94080.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

381_2019_4304_MOESM1_ESM.docx (14 kb)
ESM 1 (DOCX 14 kb)


  1. 1.
    Plimpton SR, Stence N, Hemenway M, Hankinson TC, Foreman N, Liu AK (2015) Cerebral radiation necrosis in pediatric patients. Pediatr Hematol Oncol 32(1):78–83CrossRefGoogle Scholar
  2. 2.
    Drezner N, Hardy KK, Wells E, Vezina G, Ho CY, Packer RJ, Hwang EI (2016) Treatment of pediatric cerebral radiation necrosis: a systematic review. J Neuro-Oncol 130(1):141–148CrossRefGoogle Scholar
  3. 3.
    Packer RJ, Zimmerman RA, Kaplan A, Wara WM, Rorke LB, Selch M, Goldwein J, Allen JA, Boyett J, Albright AL, Finlay JL, Hammond GD (1993) Early cystic/necrotic changes after hyperfractionated radiation therapy in children with brain stem gliomas. Data from the Childrens Cancer Group. Cancer. 71(8):2666–2674CrossRefGoogle Scholar
  4. 4.
    Nelson MD Jr, Soni D, Baram TZ (1994) Necrosis in pontine gliomas: radiation induced or natural history? Radiology. 191(1):279–282CrossRefGoogle Scholar
  5. 5.
    Alexiou GA, Tsiouris S, Kyritsis AP, Voulgaris S, Argyropoulou MI, Fotopoulos AD (2009) Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities. J Neuro-Oncol 95(1):1–11CrossRefGoogle Scholar
  6. 6.
    Dequesada IM, Quisling RG, Yachnis A, Friedman WA (2008) Can standard magnetic resonance imaging reliably distinguish recurrent tumor from radiation necrosis after radiosurgery for brain metastases? A radiographic-pathological study. Neurosurgery. 63(5):898–903 discussion 904CrossRefGoogle Scholar
  7. 7.
    Li YQ, Ballinger JR, Nordal RA, Su ZF, Wong CS (2001) Hypoxia in radiation-induced blood-spinal cord barrier breakdown. Cancer Res 61(8):3348–3354PubMedGoogle Scholar
  8. 8.
    Wong CS, Van der Kogel AJ (2004) Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. Mol Interv 4(5):273–284CrossRefGoogle Scholar
  9. 9.
    Bartholdi D, Rubin BP, Schwab ME (1997) VEGF mRNA induction correlates with changes in the vascular architecture upon spinal cord damage in the rat. Eur J Neurosci 9(12):2549–2560CrossRefGoogle Scholar
  10. 10.
    Delishaj D, Ursino S, Pasqualetti F, Cristaudo A, Cosottini M, Fabrini MG, Paiar F (2017) Bevacizumab for the treatment of radiation-induced cerebral necrosis: a systematic review of the literature. J Clin Med Res 9(4):273–280CrossRefGoogle Scholar
  11. 11.
    Nordal RA, Nagy A, Pintilie M, Wong CS (2004) Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor. Clin Cancer Res 10(10):3342–3353CrossRefGoogle Scholar
  12. 12.
    Lubelski D, Abdullah KG, Weil RJ, Marko NF (2013) Bevacizumab for radiation necrosis following treatment of high grade glioma: a systematic review of the literature. J Neuro-Oncol 115(3):317–322CrossRefGoogle Scholar
  13. 13.
    Torcuator R, Zuniga R, Mohan YS, Rock J, Doyle T, Anderson J, Gutierrez J, Ryu S, Jain R, Rosenblum M, Mikkelsen T (2009) Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neuro-Oncol 94(1):63–68CrossRefGoogle Scholar
  14. 14.
    Sadraei NH, Dahiya S, Chao ST, Murphy ES, Osei-Boateng K, Xie H, Suh JH, Peereboom DM, Stevens GHJ, Ahluwalia MS (2015) Treatment of cerebral radiation necrosis with bevacizumab: the Cleveland clinic experience. Am J Clin Oncol 38(3):304–310CrossRefGoogle Scholar
  15. 15.
    Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR, Jackson EF (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79(5):1487–1495CrossRefGoogle Scholar
  16. 16.
    Liu AK, Macy ME, Foreman NK (2009) Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys 75(4):1148–1154CrossRefGoogle Scholar
  17. 17.
    Foster KA, Ares WJ, Pollack IF, Jakacki RI (2015) Bevacizumab for symptomatic radiation-induced tumor enlargement in pediatric low grade gliomas. Pediatr Blood Cancer 62(2):240–245CrossRefGoogle Scholar
  18. 18.
    Billson AL, Walker DA (1994) Assessment of health status in survivors of cancer. Arch Dis Child 70(3):200–204CrossRefGoogle Scholar
  19. 19.
    Kumar AJ, Leeds NE, Fuller GN, van Tassel P, Maor MH, Sawaya RE, Levin VA (2000) Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology. 217(2):377–384CrossRefGoogle Scholar
  20. 20.
    Mullins ME, Barest GD, Schaefer PW, Hochberg FH, Gonzalez RG, Lev MH (2005) Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. AJNR Am J Neuroradiol 26(8):1967–1972PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Center for Cancer and Blood DisordersChildren’s Hospital ColoradoAuroraUSA
  2. 2.Morgan Adams Foundation Pediatric Brain Tumor Research Program, Department of PediatricsUniversity of Colorado School of MedicineAuroraUSA
  3. 3.Department of Radiation OncologyUniversity of Colorado School of MedicineAuroraUSA
  4. 4.Department of RadiologyChildren’s Hospital ColoradoAuroraUSA

Personalised recommendations